Imunon
Presence
Acquisition, funding and merger involving Imunon.
- Imunon will change its company name to Imunon. (posted on September 20 2022).
Executives
View the org chart displaying its 10 main executives
Most searched biographies at Imunon
- Michael Tardugno, Executive Chairman and Chief Executive Officer
- Christine Pellizzari, Director
- Frederick Fritz, Director
Popular executive movements at Imunon
- Michael Tardugno, who was Executive Chairman of the Board, is promoted to Executive Chairman and Chief Executive Officer (posted on March 13 2024).
- Corinne Le Goff, President and Chief Executive Officer and Director, has left the company (posted on March 13 2024).
- Sebastien Hazard has joined the company as Chief Medical Officer (posted on December 11 2023).
Create your alert
to follow the executive moves at Imunon.
Biotechnology
Imunon has 2,282 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Imunon
- Press Releases | IMUNON INC.
- Press Releases – IMUNON
- RSS News Feeds | Celsion Corporation
- Celsion Corporation Issues Letter to Stockholders | Celsion Corporation
- Celsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study | Celsion Corporation
- Celsion Corporation Restructures its Strategic Loan Facility | Celsion Corporation
- Press Releases | Celsion Corporation
- Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update | Celsion Corporation
- Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020 | Celsion Corporation
- Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival | Celsion Corporation
- View more press releases Close
Social media about Imunon
- Imunon on Wikipedia, Google News & Yahoo Finance
- Imunon on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Michael Tardugno 
